Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets
Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.
- The growing burden of neurological disease has intensified industry-wide interest in therapies capable of protecting neurons, preserving brain function and addressing disease progression at a biological level.
- Quantum BioPharma’s flagship pharmaceutical subsidiary, Lucid Psycheceuticals Inc., is advancing LUCID-MS, a patented new chemical entity being developed for an unmet need in multiple sclerosis.
- The company has also expanded its presence in a consumer ready product in the field of alcohol health and sobriety through its involvement with unbuzzd(TM), an innovative, clinically validated alcohol metabolism accelerator designed to help sober people up faster.
Neurological disorders are increasingly recognized as one of the world’s most significant healthcare challenges as aging populations and rising disease prevalence place growing pressure on healthcare systems globally. According to the World Health Organization, neurological conditions are now the leading cause of illness and disability worldwide, affecting more than one-third of the global population. Despite advances in treatment, many currently approved therapies for neurodegenerative diseases primarily focus on symptom management rather than directly addressing underlying neurodegeneration, leaving substantial unmet medical needs across the sector. Current drugs for multiple sclerosis do not address loss of mobility and function which remains an unmet patient need today.
Against this backdrop, Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), is advancing a novel, new chemical entity patented approach to multiple sclerosis..
The growing burden of neurological disease has intensified industry-wide interest in therapies capable of protecting neurons, preserving brain function and addressing disease progression at a biological level. Research that neurological disorders represent the leading cause of disability-adjusted life years globally, underscoring the expanding societal and economic impact of diseases such as Multiple Sclerosis, Alzheimer’s disease and Parkinson’s disease. In the United States alone, neurological disorders generate billions of dollars annually in healthcare costs, lost productivity and long-term care expenses. Researchers and biotechnology companies are increasingly pursuing therapies designed not only to treat symptoms but also to target the mechanisms responsible for neuronal injury and degeneration.
Quantum BioPharma operates as a biopharmaceutical company focused on developing treatments and biotech solutions targeting neurodegenerative, metabolic and alcohol misuse disorders. The company’s business strategy combines clinical-stage therapeutic development with additional biotech and strategic investment initiatives designed to diversify potential value creation opportunities. The company’s lead focus is neurological disease and the advancement of therapies that could potentially address major unmet needs worldwide.
Quantum BioPharma’s flagship pharmaceutical subsidiary, Lucid Psycheceuticals Inc., is advancing LUCID-MS, a patented new chemical entity being developed for multiple sclerosis. Unlike many currently approved MS therapies that primarily target immune system modulation, Lucid-MS is designed as a neuroprotective therapy focused on preventing myelin degradation, a key driver of neurological damage in multiple sclerosis.
Quantum BioPharma has reported that preclinical animal model studies demonstrated the compound’s ability to prevent and reverse myelin degradation in disease models. One company-produced video reports on a mouse regaining its ability to walk after treatment witih LUCID-MS.
While Lucid-MS represents the company’s lead pharmaceutical program, Quantum BioPharma has also expanded its presence into metabolic and alcohol misuse-related wellness technologies through its involvement with unbuzzd(TM), an innovative, clinically validated alcohol metabolism accelerator designed to help sober people up faster. The company developed the original unbuzzd intellectual property and later spun out the over-the-counter version to Unbuzzd Wellness Inc., while retaining a significant ownership position and royalty rights tied to future sales.
According to Quantum BioPharma, unbuzzd was developed by a research and development team specializing in pharmacology and medicine and is intended to help accelerate alcohol metabolism, restore mental alertness and reduce symptoms associated with alcohol consumption. The product contains a proprietary blend of vitamins, minerals and supplements designed to support liver and brain function after drinking. The company positions the product not simply as a hangover remedy but as part of a broader effort to address societal burdens associated with alcohol misuse and intoxication.
The company has highlighted growing scientific validation surrounding unbuzzd in a first of its kind clinical study. In March 2026, Quantum BioPharma announced the publication of a peer-reviewed, double-blind, randomized, placebo-controlled crossover clinical study evaluating unbuzzd. According to the published findings, participants receiving unbuzzd experienced reductions in blood alcohol concentration more than 40% faster within the first 30 minutes compared with placebo. The study also reported improvements in alertness, reduced mental fatigue and reductions in hangover symptoms without reported adverse side effects.
Quantum BioPharma maintains financial participation in the commercialization of unbuzzd through both equity ownership and royalty agreements. The company disclosed that it retains approximately 20% ownership in Unbuzzd Wellness Inc., along with royalty rights equal to 7% of product sales until cumulative royalty payments reach $250 million, after which the royalty rate falls to 3% in perpetuity. The structure provides Quantum BioPharma with potential long-term exposure to the commercialization success of the product while maintaining rights related to pharmaceutical and medical-use formulations.
The company has also emphasized the commercial leadership supporting the unbuzzd platform. Quantum BioPharma notes that the initiative involves executives and advisors with backgrounds at major consumer beverage companies, including Co-Chair Gerry David, previously the CEO of Celsius Holdings, and John Duffy, previously with The Coca-Cola Company. Another advisor connected to the product is Kevin Harrington, one of the original investors featured on “Shark Tank.”
As neurological disease prevalence continues rising worldwide, biotechnology companies pursuing differentiated therapeutic approaches and adjacent wellness technologies may attract increasing industry attention. Quantum BioPharma’s strategy combines clinical-stage neurodegenerative drug development targeting helping patients get back the mobility and control of their bodies they have lost due to MS with broader commercial initiatives targeting alcohol misuse and metabolic wellness making people sober faster.
For more information, visit www.QuantumBioPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.
- The growing burden of neurological disease has intensified industry-wide interest in therapies capable of protecting neurons, preserving brain function and addressing disease progression at a biological level.
- Quantum BioPharma’s flagship pharmaceutical subsidiary, Lucid Psycheceuticals Inc., is advancing LUCID-MS, a patented new chemical entity being developed for an unmet need in multiple sclerosis.
- The company has also expanded its presence in a consumer ready product in the field of alcohol health and sobriety through its involvement with unbuzzd(TM), an innovative, clinically validated alcohol metabolism accelerator designed to help sober people up faster.
Neurological disorders are increasingly recognized as one of the world’s most significant healthcare challenges as aging populations and rising disease prevalence place growing pressure on healthcare systems globally. According to the World Health Organization, neurological conditions are now the leading cause of illness and disability worldwide, affecting more than one-third of the global population. Despite advances in treatment, many currently approved therapies for neurodegenerative diseases primarily focus on symptom management rather than directly addressing underlying neurodegeneration, leaving substantial unmet medical needs across the sector. Current drugs for multiple sclerosis do not address loss of mobility and function which remains an unmet patient need today.
Against this backdrop, Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), is advancing a novel, new chemical entity patented approach to multiple sclerosis..
The growing burden of neurological disease has intensified industry-wide interest in therapies capable of protecting neurons, preserving brain function and addressing disease progression at a biological level. Research that neurological disorders represent the leading cause of disability-adjusted life years globally, underscoring the expanding societal and economic impact of diseases such as Multiple Sclerosis, Alzheimer’s disease and Parkinson’s disease. In the United States alone, neurological disorders generate billions of dollars annually in healthcare costs, lost productivity and long-term care expenses. Researchers and biotechnology companies are increasingly pursuing therapies designed not only to treat symptoms but also to target the mechanisms responsible for neuronal injury and degeneration.
Quantum BioPharma operates as a biopharmaceutical company focused on developing treatments and biotech solutions targeting neurodegenerative, metabolic and alcohol misuse disorders. The company’s business strategy combines clinical-stage therapeutic development with additional biotech and strategic investment initiatives designed to diversify potential value creation opportunities. The company’s lead focus is neurological disease and the advancement of therapies that could potentially address major unmet needs worldwide.
Quantum BioPharma’s flagship pharmaceutical subsidiary, Lucid Psycheceuticals Inc., is advancing LUCID-MS, a patented new chemical entity being developed for multiple sclerosis. Unlike many currently approved MS therapies that primarily target immune system modulation, Lucid-MS is designed as a neuroprotective therapy focused on preventing myelin degradation, a key driver of neurological damage in multiple sclerosis.
Quantum BioPharma has reported that preclinical animal model studies demonstrated the compound’s ability to prevent and reverse myelin degradation in disease models. One company-produced video reports on a mouse regaining its ability to walk after treatment witih LUCID-MS.
While Lucid-MS represents the company’s lead pharmaceutical program, Quantum BioPharma has also expanded its presence into metabolic and alcohol misuse-related wellness technologies through its involvement with unbuzzd(TM), an innovative, clinically validated alcohol metabolism accelerator designed to help sober people up faster. The company developed the original unbuzzd intellectual property and later spun out the over-the-counter version to Unbuzzd Wellness Inc., while retaining a significant ownership position and royalty rights tied to future sales.
According to Quantum BioPharma, unbuzzd was developed by a research and development team specializing in pharmacology and medicine and is intended to help accelerate alcohol metabolism, restore mental alertness and reduce symptoms associated with alcohol consumption. The product contains a proprietary blend of vitamins, minerals and supplements designed to support liver and brain function after drinking. The company positions the product not simply as a hangover remedy but as part of a broader effort to address societal burdens associated with alcohol misuse and intoxication.
The company has highlighted growing scientific validation surrounding unbuzzd in a first of its kind clinical study. In March 2026, Quantum BioPharma announced the publication of a peer-reviewed, double-blind, randomized, placebo-controlled crossover clinical study evaluating unbuzzd. According to the published findings, participants receiving unbuzzd experienced reductions in blood alcohol concentration more than 40% faster within the first 30 minutes compared with placebo. The study also reported improvements in alertness, reduced mental fatigue and reductions in hangover symptoms without reported adverse side effects.
Quantum BioPharma maintains financial participation in the commercialization of unbuzzd through both equity ownership and royalty agreements. The company disclosed that it retains approximately 20% ownership in Unbuzzd Wellness Inc., along with royalty rights equal to 7% of product sales until cumulative royalty payments reach $250 million, after which the royalty rate falls to 3% in perpetuity. The structure provides Quantum BioPharma with potential long-term exposure to the commercialization success of the product while maintaining rights related to pharmaceutical and medical-use formulations.
The company has also emphasized the commercial leadership supporting the unbuzzd platform. Quantum BioPharma notes that the initiative involves executives and advisors with backgrounds at major consumer beverage companies, including Co-Chair Gerry David, previously the CEO of Celsius Holdings, and John Duffy, previously with The Coca-Cola Company. Another advisor connected to the product is Kevin Harrington, one of the original investors featured on “Shark Tank.”
As neurological disease prevalence continues rising worldwide, biotechnology companies pursuing differentiated therapeutic approaches and adjacent wellness technologies may attract increasing industry attention. Quantum BioPharma’s strategy combines clinical-stage neurodegenerative drug development targeting helping patients get back the mobility and control of their bodies they have lost due to MS with broader commercial initiatives targeting alcohol misuse and metabolic wellness making people sober faster.
For more information, visit www.QuantumBioPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
